Grant: CIHR Fellowship
McMaster University
$90,000.00
Pulmonary 1H Magnetic Resonance Imaging of Severe Asthma
EF 2015-16
Résumé
Severe asthma accounts for a large majority of hospital visits and admissions in Canada and this has enormous costs for the asthma patient, their caregivers and employers and the healthcare system. Unfortunately, for many patients with asthma, current therapies do not improve their symptoms or their risk of disease worsening, necessitating hospital visits, lost work/school days and poor quality of life. To decrease the staggering burden on patients and the health care system, we want to develop new imaging measurements of asthma that can be used to improve patient outcomes. We will develop physiologically-relevant MRI biomarkers of asthma treatment response, disease progression and control. We think that MRI measurements will be related to structural abnormalities in the asthmatic lung, inflammatory markers, airflow obstruction, control and quality of life. Importantly, we also think these measurements will be more sensitive to disease abnormalities in asthma than currently used clinical tools. One major advantage of this approach is that it can be easily implemented in most medical imaging centres with access to a MRI scanner. This advantage is fundamentally important, making proton MRI approaches likely to find a place in the clinical setting. Unfortunately, previous pulmonary imaging initiatives have not been practical for widespread routine clinical use, mainly due to the requirements for highly specialized equipment. Our advances are very likely to impact asthma management and how new treatments will be developed and evaluated. By "seeing" asthma and how it regionally responds to treatment, and how it changes over time, there is increased potential for more effective treatment that can improve patient outcomes. Based on the enormous burden on the health care system, the vastly diminished quality of life, and increased morbidity of patients with asthma, MRI biomarkers that help improve outcomes have high potential clinical and economic impact.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
338794
Name
Svenningsen Sarah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Pulmonary 1H Magnetic Resonance Imaging of Severe Asthma
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Asthma; Proton Mri; Pulmonary Imaging
Abstract
Severe asthma accounts for a large majority of hospital visits and admissions in Canada and this has enormous costs for the asthma patient, their caregivers and employers and the healthcare system. Unfortunately, for many patients with asthma, current therapies do not improve their symptoms or their risk of disease worsening, necessitating hospital visits, lost work/school days and poor quality of life. To decrease the staggering burden on patients and the health care system, we want to develop new imaging measurements of asthma that can be used to improve patient outcomes. We will develop physiologically-relevant MRI biomarkers of asthma treatment response, disease progression and control. We think that MRI measurements will be related to structural abnormalities in the asthmatic lung, inflammatory markers, airflow obstruction, control and quality of life. Importantly, we also think these measurements will be more sensitive to disease abnormalities in asthma than currently used clinical tools. One major advantage of this approach is that it can be easily implemented in most medical imaging centres with access to a MRI scanner. This advantage is fundamentally important, making proton MRI approaches likely to find a place in the clinical setting. Unfortunately, previous pulmonary imaging initiatives have not been practical for widespread routine clinical use, mainly due to the requirements for highly specialized equipment. Our advances are very likely to impact asthma management and how new treatments will be developed and evaluated. By "seeing" asthma and how it regionally responds to treatment, and how it changes over time, there is increased potential for more effective treatment that can improve patient outcomes. Based on the enormous burden on the health care system, the vastly diminished quality of life, and increased morbidity of patients with asthma, MRI biomarkers that help improve outcomes have high potential clinical and economic impact.
Competitiondate
201511
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Svenningsen, Sarah
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~